| Literature DB >> 35117515 |
Guanqun Chao1, Yue Zhu1, Lizheng Fang1.
Abstract
BACKGROUND: To clarify the risk factors of colorectal adenomas and non-adenomatous polyps by retrospective analysis.Entities:
Keywords: Colorectal adenoma (CRC); fatty liver; non-adenomatous polyp; risk factor
Year: 2020 PMID: 35117515 PMCID: PMC8797785 DOI: 10.21037/tcr.2020.01.69
Source DB: PubMed Journal: Transl Cancer Res ISSN: 2218-676X Impact factor: 1.241
Figure 1Subjects’ inclusion process.
Demographic and laboratory analysis of adenoma and non-adenomatous polyp groups
| Factor | Control group (n=545) | Non-adenomatous polyp (n=58) | Adenoma (n=115) | aP | bP | cP |
|---|---|---|---|---|---|---|
| Male gender | 330 (60.6%) | 49 (84.5%) | 90 (78.3%) | <0.001 | <0.001 | 0.442 |
| Age, years | 48.8±8.45 | 52.0±5.87 | 51.1±7.66 | <0.001 | 0.032 | 0.395 |
| BMI, kg/m2 | 24.4±3.15 | 26.1±3.37 | 25.2±2.97 | <0.001 | 0.006 | 0.096 |
| BP, mmHg | ||||||
| SBP | 122±14.8 | 123±11.9 | 122±13.7 | 0.347 | 0.593 | 0.681 |
| DBP | 73.5±11.0 | 75.6±8.93 | 75.1±10.2 | 0.105 | 0.143 | 0.733 |
| WC, cm | 85.8±9.80 | 92.3±10.3 | 88.4±9.41 | <0.001 | 0.009 | 0.0157 |
| FBG*, mmol/L | 5.12 (3.60, 15.8) | 5.37 (4.20, 13.8) | 5.32 (4.00, 11.1) | 0.013 | <0.001 | 0.879 |
| UA, mg/dL | 352±90.7 | 381±90.1 | 383±88.0 | 0.020 | <0.001 | 0.882 |
| TG*, mg/dL | 1.41 (0.380, 17.2) | 1.64 (0.560, 9.68) | 1.60 (0.540, 37.7) | 0.002 | 0.003 | 0.384 |
| TC, mg/dL | 4.98±0.937 | 4.95±0.852 | 5.13±0.978 | 0.839 | 0.135 | 0.230 |
| HDL, mg/dL | 1.16±0.294 | 1.02±0.262 | 1.10±0.290 | <0.001 | 0.070 | 0.069 |
| LDL, mg/dL | 2.82±0.762 | 2.66±0.749 | 2.80±0.728 | 0.125 | 0.772 | 0.247 |
| ALT*, IU/L | 21.0 (5.00, 181) | 27.5 (7.00, 86.0) | 23.0 (9.00, 79.0) | 0.005 | 0.133 | 0.113 |
| AST, IU/L | 20.0 (9.00, 264) | 23.0 (12.0, 52.0) | 21.0 (11.0, 82.0) | 0.011 | 0.090 | 0.294 |
| Fatty liver disease | 212 (38.9%) | 33 (56.9%) | 48 (41.7%) | 0.001 | 0.645 | 0.085 |
*, it makes sense between the groups. aP, two-sided P values for the difference between the non-adenomatous polyp group and control group; bP, two-sided P values for the difference between the adenoma group and control group; cP, two-sided P values for the difference between the adenoma group and non-adenomatous polyp group. BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; WC, Waist circumference; FBG, fast blood glucose; SUA, serum Uric acid; TC, total cholesterol; TG, triglycerides; LDL, low density lipoprotein; HDL, high density lipoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen.
Risk factors analysis of adenoma group and non-adenomatous polyp group
| Factor | Crude | Adjusted* | |||||
|---|---|---|---|---|---|---|---|
| OR | 95%CI | P | OR | 95%CI | P | ||
| Non-adenomatous polyp | |||||||
| Male gender | 3.548 | 1.790–7.858 | <0.001* | 2.416 | 1.022–6.123 | 0.051 | |
| Age | 1.047 | 1.013–1.082 | 0.006* | 1.045 | 1.009–1.083 | 0.015* | |
| BMI | 1.436 | 1.427–1.445 | <0.001* | 1.086 | 1.267–1.286 | 0.107 | |
| SBP | 1.008 | 0.989–1.026 | 0.426 | – | – | – | |
| DBP | 1.017 | 0.993–1.043 | 0.166 | – | – | – | |
| WC | 1.070 | 1.040–1.103 | <0.001* | 1.026 | 1.539–1.668 | 0.262 | |
| FBG | 1.287 | 1.096–1.504 | 0.001* | 1.133 | 1.645–1.769 | 0.174 | |
| SUA | 1.003 | 1.000–1.006 | 0.019* | 0.999 | 0.099–1.003 | 0.520 | |
| TG | 1.212 | 1..058–1.395 | 0.005* | 1.102 | 0.924–1.285 | 0.230 | |
| TC | 0.972 | 0.722–1.298 | 0.850 | – | – | – | |
| HDL | 0.142 | 0.043–0.430 | <0.001* | 0.354 | 0.908–1.258 | 0.121 | |
| LDL | 0.751 | 0.517–1.079 | 0.127 | – | – | – | |
| ALT | 1.011 | 0.998–1.023 | 0.076 | – | – | – | |
| AST | 1.006 | 0.985–1.022 | 0.447 | – | – | – | |
| FLD | 2.073 | 1.203–3.615 | 0.009* | 0.824 | 0.401–1.686 | 0.595 | |
| Adenoma | |||||||
| Male gender | 2.345 | 1.479–3.840 | <0.001* | 2.042 | 1.018–4.179 | 0.047* | |
| Age | 1.033 | 1.008–1.058 | 0.009* | 1.036 | 1.010–1.063 | 0.007* | |
| BMI | 1.080 | 1.014–1.151 | 0.017* | 1.062 | 0.984–1.146 | 0.120 | |
| SBP | 1.004 | 0.990–1.017 | 0.609 | – | – | – | |
| DBP | 1.013 | 0.995–1.032 | 0.163 | – | – | – | |
| WC | 1.021 | 1.007–1.050 | 0.010* | 0.983 | 0.954–1.013 | 0.257 | |
| FBG | 1.207 | 1.035–1.405 | 0.014* | 1.114 | 0.937–1.311 | 0.198 | |
| SUA | 1.004 | 1.002–1.006 | <0.001* | 1.002 | 0.999–1.005 | 0.197 | |
| TG | 1.135 | 1.031–1.278 | 0.023* | 1.085 | 0.986–1.222 | 0.131 | |
| TC | 1.179 | 0.955–1.453 | 0.123 | – | – | – | |
| HDL | 0.507 | 0.237–1.040 | 0.717 | – | – | – | |
| LDL | 0.962 | 0.735–1.255 | 0.777 | – | – | – | |
| ALT | 1.003 | 0.991–1.013 | 0.651 | – | – | – | |
| AST | 1.007 | 0.992–1.022 | 0.299 | – | – | – | |
| CR | 1.015 | 1.002–1.029 | 0.027* | 0.999 | 0.979–1.019 | 0.908 | |
| BUN | 1.124 | 0.918–1.372 | <0.001* | 0.940 | 0.746–1.178 | 0.593 | |
| FLD | 1.125 | 0.745–1.690 | 0.571 | – | – | – | |
Crude means only single factor regression analysis without adjusting age, gender and other factors. *, it makes sense between the groups. Gender, age, BMI, central obesity, diabetes, different levels of uric acid, high TC, high TG, high LDL-c, low HDL-c, and abnormal liver function were Adjusted. OR, odds ratio; BMI, body mass index; SUA, serum uric acid; TC, total cholesterol; HDL, high-density lipoproteins; LDL, low-density lipoproteins; LF, liver function.